Z Squared (ZSQR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
26 Jun, 2026Executive summary
The 2024 Annual Meeting will be held virtually on December 18, 2024, with voting available online, by mail, or by phone.
Proposals include director elections, auditor ratification, a reverse stock split, approval of a $20M equity agreement, and a say-on-pay vote.
The Board recommends voting in favor of all proposals and outlines procedures for voting and revoking proxies.
Voting matters and shareholder proposals
Seven directors are up for election for one-year terms.
Ratification of Astra Audit & Advisory, LLC as the new independent auditor for 2024 is proposed.
Approval sought for a reverse stock split (1-for-3 to 1-for-40) to maintain Nasdaq listing.
Shareholder approval requested for issuing up to $20M in securities under a Standby Equity Purchase Agreement.
Advisory vote on executive compensation (say-on-pay) is included.
Board of directors and corporate governance
Board consists of seven members with diverse backgrounds in life sciences, finance, and operations.
Four directors are independent per Nasdaq and SEC rules.
Board committees include Audit, Compensation, Nominating and Governance, and a Scientific Advisory Board.
Board diversity matrix disclosed in compliance with Nasdaq rules.
Latest events from Z Squared
- Cell therapy and AI platform developer faces ongoing losses but secures $30M in new funding.ZSQR
Registration filing26 Jun 2026 - Net loss narrowed, but ongoing losses and liquidity risks persist despite new capital raised.ZSQR
Q4 202426 Jun 2026 - Net loss narrowed, expenses declined, and $4.3M was raised in Series A Preferred Stock.ZSQR
Q2 202426 Jun 2026 - Large secondary resale of mining-focused digital infrastructure shares faces major financial and regulatory risks.ZSQR
Registration filing26 Jun 2026 - Net loss narrowed, expenses fell, and $5.8M was raised, but going concern risks persist.ZSQR
Q3 202426 Jun 2026 - 2025 revenue growth in technology offset by biotech losses; net loss $12.28M, merger pending.ZSQR
Q4 202526 Jun 2026 - Biopharma firm registers 3.9M shares for resale to fund R&D amid ongoing losses and high risk.ZSQR
Registration filing26 Jun 2026 - Biopharma firm seeks to commercialize novel cell therapies amid financial and listing challenges.ZSQR
Registration filing26 Jun 2026 - Net loss widened to $3.4M in Q1 2025 despite increased cash and new financing initiatives.ZSQR
Q1 202526 Jun 2026